Please ensure Javascript is enabled for purposes of website accessibility

Predicting Dendreon's Next CEO's Future

By Dave Williamson and Michael Douglass - Jun 30, 2014 at 9:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its time to play Fool in the blank

Investors in Dendreon (Nasdaq: DNDN) are used to bad news, but a change in the CEO suite has given hope new leadership can turn around the struggling prostate cancer vaccine maker.

Under his stewardship CEO John Johnson admirably cut costs, but reducing losses isn't the same as turning a profit. Competition has been an insurmountable problem for Dendreon, as Johnson & Johnson's (NYSE: JNJ) Zytiga continues to show strong 49% year over year growth totaling $512 million in quarterly sales, while Dendreon's Provenge has been stagnating near $70 million per quarter.

In this episode of Market Check-Up, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass, discuss the tenure of CEO John Johnson, why the stock's struggles aren't necesarily his fault, and give predictions of the next CEO's tenure in a Foolish game fashion.

 

David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$170.57 (0.22%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.